Absorption, Distribution, and Excretion of the Investigational Agent Orteronel (TAK-700) in Healthy Male Subjects: A Phase 1, Open-Label, Single-Dose Study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Absorption, Distribution, and Excretion of the Investigational Agent Orteronel (TAK-700) in Healthy Male Subjects: A Phase 1, Open-Label, Single-Dose Study

Published:2016-01-08 Issue:3 Volume:5 Page:180-187
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharmacology in Drug Development

Author:

Suri Ajit¹,Pusalkar Sandeepraj¹,Li Yuexian¹,Prakash Shimoga¹

Affiliation:

1. Millennium Pharmaceuticals; Inc; a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge MA USA

Funder

Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Reference30 articles.

1. International variation in prostate cancer incidence and mortality rates;Center;Eur Urol,2012

2. Cancer statistics, 2014;Siegel;CA Cancer J Clin,2014

3. Redefining hormone resistance in prostate cancer;Hoimes;Ther Adv Med Oncol,2010

4. Targeting the androgen receptor pathway in prostate cancer;Chen;Curr Opin Pharmacol,2008

5. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence;Taplin;J Cell Biochem,2004

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mass Balance of the Indoleamine 2,3‐Dioxygenase Inhibitor Navoximod (GDC-0919) in Rats and Dogs: Unexpected Cyanide Release from Imidazo[5,1-a]isoindole and Species Differences in Glucuronidation;Drug Metabolism and Disposition;2023-04-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP